{"nct_id":"NCT05287113","title":"Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2025-08","start_date":"2022-11-14","start_date_type":"ACTUAL","primary_completion_date":"2025-03-14","primary_completion_date_type":"ACTUAL","completion_date":"2026-07-10","completion_date_type":"ESTIMATED","phases":["PHASE2"],"tickers":["INCY"]}